Search

Mirati Therapeutics Inc

Suletud

SektorTervishoid

0

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

-0.05% downside

Uudiste sentiment

By Acuity

50%

50%

120 / 339 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. sept 2026, 23:41 UTC

News

Iovance Biotherapeutics granted inducement stock options for 179.75k shares to new employees, contributing to a modest decline in after-market hours.

18. sept 2026, 23:31 UTC

News

BlackRock Inc. shares are modestly lower in after-market trading amid heightened legal concerns as the DOJ considers intervention in an antitrust lawsuit against the company.

18. sept 2026, 23:26 UTC

News

State Street Corp declines in after-market trading as the U.S. Department of Justice considers intervention in a state antitrust lawsuit regarding energy price inflation.

18. sept 2026, 23:16 UTC

News

Union Pacific Corp's stock is trading higher in after-market hours following UBS's upgrade to Buy and a price target increase to $339, citing expected cargo growth.

18. sept 2026, 23:11 UTC

News

AutoNation Inc has been downgraded from Buy to Hold amid industry challenges, yet the stock is rising in after-market trading as the broader market advances.

18. sept 2026, 23:11 UTC

News

Leidos Holdings Inc. has secured an $85 million contract from the U.S. Department of War for aerospace systems design, with shares rising in after-market trading.

18. sept 2026, 23:06 UTC

News

AbbVie Inc. is experiencing a slight decline in after-market trading, positioned near the lower end of its recent trading range despite promising myeloma study results.

18. sept 2026, 23:06 UTC

News

Boeing is in talks with NASA to expand its Starliner program, potentially adding ten or more flights, as the stock moves higher in after-hours trading.

18. sept 2026, 23:06 UTC

News

Chevron Corp has declined in after-market trading, despite Goldman Sachs raising its price target to $240 and Piper Sandler setting an even higher target of $243.

18. sept 2026, 23:06 UTC

News

Okta Inc appointed Helen Riley to its board, enhancing leadership as shares rise in after-market trading, aligning with a broader market advance.

18. sept 2026, 23:06 UTC

News
Social Media

Nike shares are advancing in after-market hours despite recent challenges, including a significant decline and hitting a 12-year low.

18. sept 2026, 23:06 UTC

News

General Motors Co is advancing in after-market trading following its decision to reinstate Apple’s CarPlay and Android Auto in its vehicles.

18. sept 2026, 23:06 UTC

News

Medtronic PLC raised its fiscal 2027 profit forecast and reported first-quarter revenue of $9.756 billion, exceeding expectations, in after-market trading.

18. sept 2026, 23:06 UTC

News

RTX Corp's backlog hit a record $289 billion, with the stock advancing in after-market trading, despite remaining below its 20-day moving average.

18. sept 2026, 23:06 UTC

News

Celsius Holdings Inc shares are higher in after-market trading, continuing a positive trend despite ongoing legal scrutiny over its Alani Nu product line.

18. sept 2026, 23:01 UTC

News
Social Media

Northrop Grumman targets $10 billion in annual international sales by 2031, while shares trade lower in after-market hours.

18. sept 2026, 23:01 UTC

News

Kimberly-Clark Corp plans to divest assets related to its $40 billion Kenvue acquisition to address EU antitrust concerns, with shares modestly higher in after-market trading.

18. sept 2026, 23:01 UTC

Social Media
News

Accenture PLC announced a $1 billion partnership with Anthropic to enhance AI evaluation capabilities, leading to a sharp advance in shares during after-market hours.

18. sept 2026, 23:01 UTC

News

Bitcoin is sharply higher, trading well above its previous close amid a rally in the cryptocurrency market, driven by strong investor sentiment and recent Fed announcements.

18. sept 2026, 23:01 UTC

News

Ethereum is advancing sharply, continuing its upward trajectory alongside a broader cryptocurrency rally, despite earlier pulling back from a session high.

18. sept 2026, 23:01 UTC

News

Ethereum is advancing sharply, remaining significantly higher since Thursday's close, as the cryptocurrency market rallies alongside Bitcoin surpassing $81k.

18. sept 2026, 23:01 UTC

News

Sharply higher amid strong investor sentiment and Fed announcements.

18. sept 2026, 23:01 UTC

News
Social Media

Wendy's Co shares are trading modestly higher in after-market hours despite concerns over Meritage Hospitality Group's Chapter 11 bankruptcy filing affecting 314 locations.

18. sept 2026, 22:51 UTC

News

Lockheed Martin Corp receives an $871.2 million contract modification for F-35 support, contributing to a modest after-market hours gain.

18. sept 2026, 22:51 UTC

News

Hf Foods Group Inc. has terminated its $100 million at-the-market equity offering program, leading to a sharp decline in after-market trading.

18. sept 2026, 22:01 UTC

News

Simply Good Foods Co is facing a securities fraud class action lawsuit, contributing to a modest decline in after-market trading following concerns over OWYN's sales performance.

18. sept 2026, 21:41 UTC

News

Amneal Pharmaceuticals received FDA approval for its lanreotide injection, launching the product immediately, driving shares higher in after-market hours.

18. sept 2026, 21:03 UTC

Macro News
News
Macro Event

The Bank of Japan raised its key interest rate to 1.25%, boosting the USD/JPY pair, which is trading higher above Thursday's close.

18. sept 2026, 21:01 UTC

News

Navient Corp is seeing a modest increase in after-market trading, reflecting routine performance and placing the price around the middle of its one-month range.

18. sept 2026, 21:01 UTC

News
Macro Event
Correlated Moves

The Bank of Japan raised its key short-term interest rate to 1.25%, causing GBP/JPY to trade modestly higher, though still below its 20-day moving average.

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD  -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

0

Osta

5

Hoia

0

Müü

Sentiment

By Acuity

120 / 339 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

$

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.